Enhancing regulatory capability through a blended delivery learning and development framework: an empirical Australian example

The Australian Pesticides and Veterinary Medicines Authority (APVMA) is a Commonwealth statutory authority responsible for the regulation of agricultural and veterinary chemical products in Australia. Effective regulation is built on engaging with risk in alignment with the relevant legislation, and requires a combination of core public service, foundation, and technical skills, in addition to management and leadership capabilities. Mapping skills, competencies, and capabilities provided the scaffolding for the 2019-21 APVMA Learning and Development Framework (the Framework). As the Framework was established to support blended delivery of distance and face-to-face learning activities, it was largely uninterrupted due to the COVID-19 pandemic as the public service increasingly pivoted to online learning.

Knowledge, Attitude, and Practices of Moroccan Retail Pharmacists towards Veterinary Medicines

This is the first study conducted in Morocco to assess knowledge, attitude, and practices of retail pharmacists regarding veterinary medicines. It is a cross-sectional study. Two types of multiple-choice questionnaires were distributed to pharmacists depending on whether or not they dispense veterinary medicines. A total of 143 pharmacists were involved in this study. The percentage of retail pharmacists who dispensed veterinary medicines was estimated at 23.1%. Less than half of respondents were highly satisfied regarding their knowledge of veterinary pharmacy. Besides, 39.4% of retail pharmacists were at ease giving advice in general while dispensing veterinary medicines, and 73% were knowledgeable on parasiticides. Approximately, 94% of retail pharmacists expressed their need to improve their knowledge of veterinary pharmacy. Our study also revealed that 48.5% of pharmacists dispensed veterinary medicine daily. This study demonstrated that involvement of retail pharmacists in dispensing veterinary medicines was poor. The need for training programs on veterinary pharmacy expressed by Moroccan retail pharmacists was high.

Functional analysis of Hypoxylon pulicicidum genes required for heterologous biosynthesis of nodulisporic acids

<p>Nature holds some of the greatest secrets in drug design and development and the ability to access these trade secrets has been revolutionised by modern bioengineering technologies. In order to exploit these technologies it is essential to understand what genes are involved in compound production and the enzymatic steps that limit flux to the desired product. This thesis describes the discovery of four secondary-metabolic enzymatic steps involved in the biosynthesis of a group of valuable natural products known as nodulisporic acids. Nodulisporic acids are known for their potent insecticidal activities; however, biosynthesis of these compounds by the natural fungal producer, Hypoxylon pulicicidum (Nodulisporium sp.), is exceptionally difficult and has prevented the commercial development of novel nodulisporic acid-containing veterinary medicines and crop protects. To discover how nodulisporic acids are biosynthesized: 1. the H. pulicicidum genome was sequenced 2. a gene cluster responsible for nodulisporic acid production was predicted 3. genes in the cluster were functionally characterised by pathway reconstitution in a common, fast growing mould, Penicillium paxilli In turn, four genes involved in the biosynthesis of the nodulisporic acid core compound, nodulisporic acid F, have been functionally characterised. The four genes encode a geranylgeranyl transferase (NodC), a flavin adenine dinucleotide-dependent oxygenase (NodM), an indole diterpene cyclase (NodB) and a cytochrome P450 oxygenase (NodW). Two of the gene products (NodM and NodW) catalyse two previously unreported reactions that provide the enzymatic basis of the biosynthetic branch point unique to nodulisporic acid biosynthesis. From here, future efforts will explore how these genes can be engineered to overcome flux bottlenecks and enable production of significantly increased, and even industrially relevant, product titres.</p>

Functional analysis of Hypoxylon pulicicidum genes required for heterologous biosynthesis of nodulisporic acids

<p>Nature holds some of the greatest secrets in drug design and development and the ability to access these trade secrets has been revolutionised by modern bioengineering technologies. In order to exploit these technologies it is essential to understand what genes are involved in compound production and the enzymatic steps that limit flux to the desired product. This thesis describes the discovery of four secondary-metabolic enzymatic steps involved in the biosynthesis of a group of valuable natural products known as nodulisporic acids. Nodulisporic acids are known for their potent insecticidal activities; however, biosynthesis of these compounds by the natural fungal producer, Hypoxylon pulicicidum (Nodulisporium sp.), is exceptionally difficult and has prevented the commercial development of novel nodulisporic acid-containing veterinary medicines and crop protects. To discover how nodulisporic acids are biosynthesized: 1. the H. pulicicidum genome was sequenced 2. a gene cluster responsible for nodulisporic acid production was predicted 3. genes in the cluster were functionally characterised by pathway reconstitution in a common, fast growing mould, Penicillium paxilli In turn, four genes involved in the biosynthesis of the nodulisporic acid core compound, nodulisporic acid F, have been functionally characterised. The four genes encode a geranylgeranyl transferase (NodC), a flavin adenine dinucleotide-dependent oxygenase (NodM), an indole diterpene cyclase (NodB) and a cytochrome P450 oxygenase (NodW). Two of the gene products (NodM and NodW) catalyse two previously unreported reactions that provide the enzymatic basis of the biosynthetic branch point unique to nodulisporic acid biosynthesis. From here, future efforts will explore how these genes can be engineered to overcome flux bottlenecks and enable production of significantly increased, and even industrially relevant, product titres.</p>

Novelties of the legislation on veterinary medicinal products

The article is devoted to the analysis of the latest innovations in the legislation on veterinary medicine, namely the regulation of the production, distribution and use of veterinary medicines. The adoption of the new Law of Ukraine “On Veterinary Medicine” is caused by the need to approximate the relevant national legislation with the legislation of the European Union to fulfill Ukraine’s international obligations under the Association Agreement. This law reflects the latest trends in the development of legislation on veterinary medicinal products in the European Union. The article pays attention to the strengthening of state regulation of production and distribution of veterinary medicines, in particular the introduction of licensing of imports, wholesale and retail sales of these medicines in Ukraine, due to the need to combat counterfeiting and veterinary medicinal products of dubious quality. It is also noted that the changes in the procedure of state registration of veterinary medicines provided by this law will on the one hand reduce the administrative burden on business due to the transition to indefinite state registration of veterinary drugs, and on the other hand new requirements for the registration dossier will improve the safety, quality and efficacy of veterinary medicinal products. New requirements for the use of antibiotics are analyzed. Attention is drawn to the fact that along with the regulation of the use of antibiotics in animal husbandry, it is also necessary to regulate in more detail the issues of control of the circulation of active substances (active pharmaceutical ingredients). The article also deals with the mechanism of veterinary pharmacovigilance, which is new for Ukraine. At the same time, it is necessary to study the practical experience of implementing the European model of pharmaco to improve the relevant legislation in Ukraine.

A Review of UK-Registered and Candidate Vaccines for Bovine Respiratory Disease

Vaccination is widely regarded as a cornerstone in animal or herd health and infectious disease management. Nineteen vaccines against the major pathogens implicated in bovine respiratory disease are registered for use in the UK by the Veterinary Medicines Directorate (VMD). However, despite annual prophylactic vaccination, bovine respiratory disease is still conservatively estimated to cost the UK economy approximately £80 million per annum. This review examines the vaccine types available, discusses the surrounding literature and scientific rationale of the limitations and assesses the potential of novel vaccine technologies.

A Comparative Analysis of Cost and Affordability between Veterinary and Human Pharmaceutical Drugs in India

To analyze the comparison of cost and affordability between veterinary and human drugs in India. A comparative study was conducted in two regions of Chennai based on a simple random sampling technique. Both Veterinary and human drugs were collected from private veterinary and Human drug pharmacies. Price and availability data of veterinary medicines and human medicines were collected from private sector retail pharmacies. As per the data analysis, descriptive statistics are used. The comparison of various antibiotic, anti-helminthic, anti-inflammatory, anti-fungal, anti-histamine, anti-tick drug prices used in humans and Animals. The variation of a single unit Amoxicillin drug for veterinary costs Rs.30 whereas in Humans, the same drug costs to Rs.18.6.Cephalexin, ciprofloxacin, Sulfamethoxazole, tetracycline, clindamycin drugs showed a higher cost range in veterinary than in human drugs which had a difference of Rs.9 on average. Doxycycline, Chlorpheniramine, aspirin, Clotrimazole were the only veterinary drug cheaper than their similar human combination. The veterinary drugs are too expensive and we must take certain steps to avoid those high prices. Drug Regulation policies must be implemented for a veterinary drug similar to a human drug. Keywords: Veterinary Drugs, Human Drugs, Price, Affordability.

Contamination methods of milk with pesticides residues and veterinary drugs

The use of agricultural pesticides is very important in improving production, but the residue of these pesticides on crops have a serious health effect on humans. On the other hand, there is another type of pollutants resulting from the use of veterinary medicines, as well as heavy metals and mycotoxins that also result in health risks to humans due to their consumption of milk and dairy products. Milk is an important and necessary food for the body as it is consumed daily by many people because its contain fat, protein, vitamin, and minerals. In this work, we present a review of most scientific articles from 1964 until 2020, related to evaluating milk contamination with various chemicals, especially pesticides and veterinary drugs. We observe from many research papers at different country in the world Lingering presence detectable values of chemical contaminate The maximum remainder, as a final result of this review paper we need to establish monitor program system for all chemical contaminate residue in milk and many food type to improve safety and reduce the risk for consumers in Iraq.

A Review of Registered and Candidate Vaccines for Bovine Respiratory Disease in the UK

Vaccination is widely regarded as a cornerstone in animal or herd health and infectious disease management. Nineteen vaccines against the major pathogens implicated in bovine respiratory disease are registered for use in the UK by the Veterinary Medicines Directorate (VMD). However, despite annual prophylactic vaccination, bovine respiratory disease is still conservatively estimated to cost the UK economy approximately &pound;80 million per annum. This review examines the vaccine types available, discusses the surrounding literature and scientific rationale of the limitations and assesses the potential of novel vaccine technologies.

Comparison of Antimicrobial Treatment Incidence Quantification Based on Detailed Field Data on Animal Level with the Standardized Methodology of the European Medicines Agency in Veal Calves, Switzerland, 2016–2018

Precise quantification of antimicrobial treatment incidence (TI) is crucial for benchmarking. Two widespread methods for treatment incidence quantification were compared for agreement. Field data were obtained from 38 veal farms from 2016 to 2018 (1905 calves, 1864 treatments). Calculation of TIswiss for calves was based on detailed treatment records using pharmacokinetic values from the Swiss Veterinary Medicines Compendium. The method published by the European Medicines Agency was used to calculate TI in defined daily doses (TIDDD). For each calf and treatment, TIswiss and TIDDD were calculated on level of the antimicrobial class, drug, application route, and farm. The quotient (Q) of TIswiss and TIDDD was calculated. Divergence in results between the two methods of ≤25% was arbitrarily set as good agreement. The agreement between TIswiss and TIDDD was mostly good. On class level, good agreement was observed for treatments representing 71.5% of the TIDDD, and 74.5% of the total TIDDD on drug level. Poor agreement was mainly observed for tylosin and sulfadimidine. The agreement was better for parenteral than for oral treatments (81.6% vs. 72.3%). For practically orientated calculation on farm level, good agreement was observed (77.5% of the TIDDD). The TIDDD method showed mostly good agreement, especially for parenteral treatments.